Targeting macrophage necroptosis in vulnerable plaques
Project Lead
Dr Denuja Karunakaran, Monash University
Project Team
Dr Alex Pokrassen, Monash University; Dr Narmadaa Thyagarajan, Monash University
Project Summary
Problem
Atherosclerosis, a leading cause of cardiovascular disease (CVD), often results in severe outcomes like heart attacks and strokes due to plaque instability and rupture. Current diagnostic methods lack specificity in identifying vulnerable plaques, hindering timely intervention to prevent CVD events.
Solution
Led by Dr. Denuja Karunakaran at Monash University, this project aims to investigate the role of macrophage necroptosis—a programmed cell death pathway—in atherothrombosis and plaque rupture. The study proposes to develop a diagnostic assay (ELISA) to measure active MLKL levels in human sera and explore targeted drug delivery to macrophages using cell-specific nanoparticles. These efforts could potentially lead to new therapeutic strategies targeting necroptosis and improve specificity in diagnosing plaque instability.
Impact
By focusing on necroptosis as both a therapeutic target and diagnostic biomarker, this research could revolutionise CVD management. Successful outcomes may yield new preclinical therapeutics and diagnostic assays, enhancing early detection of unstable plaques and enabling more effective interventions. Furthermore, the development of targeted therapies and diagnostic tools has the potential to reduce healthcare costs associated with CVD, benefiting both patients and healthcare systems. Engaging clinicians and CVD patients ensures that the study addresses critical clinical needs and aligns with patient concerns, fostering a collaborative approach towards advancing cardiovascular health.